← Back to Screener
Gilead Sciences Inc (GILD)
Price$129.16
Value ScoreC
Growth ScoreB
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-5.29%
Price vs S&P 500 (4W)-1.64%
VGM Score56.04
Market Capitalization$160.36B
P/E Ratio (Annual)18.84x
Indicated Dividend Yield (Annual)2.54%
All Metrics
P/CF (Annual)16.01x
Book Value / Share (Quarterly)$18.93
P/TBV (Annual)26.60x
Indicated Dividend (Annual)$3.28
Revenue Growth (3Y)2.57%
Cash Flow / Share (Quarterly)$8.07
Payout Ratio (TTM)97.92%
Price vs S&P 500 (YTD)-2.93%
Gross Margin (TTM)79.35%
Net Profit Margin (TTM)31.00%
EPS (TTM)$7.35
10-Day Avg Trading Volume9.02M
EPS Excl Extra (TTM)$7.35
Revenue Growth (5Y)3.58%
EPS (Annual)$6.78
Dividend / Share (Annual)$3.22
ROI (Annual)17.86%
Gross Margin (Annual)78.84%
Net Profit Margin (5Y Avg)18.22%
Cash / Share (Quarterly)$6.15
P/E Basic Excl Extra (TTM)17.40x
Revenue Growth QoQ (YoY)4.39%
EPS Growth (5Y)133.64%
P/E Normalized (Annual)18.84x
ROA (Last FY)14.42%
Revenue Growth TTM (YoY)3.48%
EBITD / Share (TTM)$8.72
ROE (5Y Avg)23.19%
Operating Margin (TTM)34.88%
Cash Flow / Share (Annual)$7.62
P/B Ratio6.82x
P/B Ratio (Quarterly)7.36x
Net Income / Employee (Annual)$500,600
EV / Revenue (TTM)5.88x
Net Interest Coverage (TTM)44.73x
ROA (TTM)16.06%
EPS Growth QoQ (YoY)54.29%
EV / EBITDA (TTM)16.01x
EPS Incl Extra (Annual)$6.78
Current Ratio (Annual)1.55x
Quick Ratio (Quarterly)1.31x
3-Month Avg Trading Volume6.77M
52-Week Price Return16.93%
EV / Free Cash Flow (Annual)18.50x
P/E Incl Extra (TTM)17.40x
Revenue / Employee (TTM)$1,749,200
Tangible BV / Share (Quarterly)$5.74
P/S Ratio (Annual)5.45x
Asset Turnover (Annual)0.50x
52-Week High$157.29
Operating Margin (5Y Avg)26.21%
EPS Excl Extra (Annual)$6.78
CapEx CAGR (5Y)-2.83%
Tangible BV CAGR (5Y)-7.13%
26-Week Price Return2.64%
Quick Ratio (Annual)1.06x
13-Week Price Return-11.01%
Total Debt / Equity (Annual)1.10x
Current Ratio (Quarterly)1.97x
Enterprise Value$174.91B
Revenue / Share Growth (5Y)3.72%
Asset Turnover (TTM)0.52x
Book Value / Share Growth (5Y)4.74%
Revenue / Employee (Annual)$1,731,900
Inventory Turnover (Annual)3.58x
Pretax Margin (Annual)33.27%
Cash / Share (Annual)$6.15
3-Month Return Std Dev21.77%
Gross Margin (5Y Avg)78.00%
Net Income / Employee (TTM)$542,200
EBITDA CAGR (5Y)18.98%
EBITDA Interim CAGR (5Y)-2.03%
ROE (Last FY)37.49%
Net Interest Coverage (Annual)120.26x
EPS Basic Excl Extra (Annual)$6.78
P/FCF (TTM)16.01x
Receivables Turnover (TTM)6.51x
EV / Free Cash Flow (TTM)17.46x
Total Debt / Equity (Quarterly)0.94x
EPS Incl Extra (TTM)$7.35
Receivables Turnover (Annual)6.31x
ROI (TTM)23.13%
Dividend Growth Rate (5Y)3.30%
P/S Ratio (TTM)5.39x
Pretax Margin (5Y Avg)22.52%
Revenue / Share (Annual)$23.46
Tangible BV / Share (Annual)$4.61
Forward P/E39.02x
Free OCF CAGR (5Y)4.69%
Price vs S&P 500 (52W)-7.44%
P/E Ratio (TTM)17.40x
EPS Growth TTM (YoY)55.49%
Year-to-Date Return5.23%
5-Day Price Return-1.48%
EPS Normalized (Annual)$6.78
ROA (5Y Avg)8.16%
Net Profit Margin (Annual)28.90%
Month-to-Date Return-3.92%
Cash Flow / Share (TTM)$6.68
EBITD / Share (Annual)$8.28
EPS Growth (3Y)23.06%
Operating Margin (Annual)34.04%
LT Debt / Equity (Annual)0.97x
P/CF (TTM)14.84x
ROI (5Y Avg)10.73%
P/E Excl Extra (TTM)17.40x
LT Debt / Equity (Quarterly)0.89x
EPS Basic Excl Extra (TTM)$7.35
P/TBV (Quarterly)24.25x
Payout Ratio (Annual)47.04%
P/B Ratio (Annual)6.71x
Dividend / Share (TTM)$4.85
Inventory Turnover (TTM)3.34x
Pretax Margin (TTM)36.08%
Book Value / Share (Annual)$18.29
Price vs S&P 500 (13W)-19.26%
Net Margin Growth (5Y)125.11%
Dividend Yield (TTM)3.76%
Beta0.35x
P/FCF (Annual)16.96x
Revenue / Share (TTM)$23.71
ROE (TTM)42.21%
52-Week Low$104.46
vGradeC
gGradeB
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 262.03est. 1.95
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.05
4.08
4.08
4.10
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
GILDGilead Sciences Inc | C | B | C | $129.16 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
| HALOHalozyme Therapeutics, Inc. | C | B | B | $71.53 |
About
Gilead Sciences develops therapies for life-threatening infectious diseases, with a portfolio focused on HIV and hepatitis B and C. The company's hepatitis C franchise, anchored by Sovaldi, remains a standard of care in combination regimens. Gilead is strategically expanding into oncology through recent acquisitions including CAR-T cell therapy Yescarta/Tecartus and solid tumor therapy Trodelvy.